Sanofi SA (ADR) (SNY), Bristol Myers Squibb Co. (BMY): Why Peregrine Pharmaceuticals (PPHM) Earnings Won’t Show Profits

More importantly for investors, the presentation also suggested a number of potential combinations that could produce beneficial health results. Bristol Myers Squibb Co. (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) have been working on therapies based on targeting the PD-1 protein, which Peregrine specifically noted as a potential downstream immunotherapy combination worth further study. Meanwhile, Gilead Sciences, Inc. (NASDAQ:GILD) could potentially find PS-targeting antibody technology helpful in studying treatments for HIV, hepatitis, and other viruses. Many shareholders hope that one of these companies will make a buyout bid for Peregrine, giving them a potential payoff without having to wait for the long process of potential approval for bavituximab.

In the Peregrine earnings release, watch for an update on the status of the phase 3 trial preparations, as well as news on any other studies. Patience will be essential for investors, but eventually, the stock could move sharply higher if Peregrine’s studies go well.

The article Why Peregrine Earnings Won’t Show Profits originally appeared on and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Gilead Sciences.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.